Log in

T2 Biosystems Stock Forecast, Price & News

-0.02 (-1.60 %)
(As of 09/21/2020 12:00 AM ET)
Today's Range
Now: $1.23
50-Day Range
MA: $1.48
52-Week Range
Now: $1.23
Volume2.41 million shs
Average Volume11.04 million shs
Market Capitalization$181.98 million
P/E RatioN/A
Dividend YieldN/A
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
Read More
T2 Biosystems logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:TTOO



Sales & Book Value

Annual Sales$8.34 million
Book Value($0.73) per share


Net Income$-59,010,000.00
Net Margins-545.93%


Market Cap$181.98 million
Next Earnings Date11/16/2020 (Estimated)
-0.02 (-1.60 %)
(As of 09/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

How has T2 Biosystems' stock price been impacted by Coronavirus?

T2 Biosystems' stock was trading at $0.4950 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TTOO stock has increased by 148.5% and is now trading at $1.23.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of T2 Biosystems?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for T2 Biosystems

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release its next quarterly earnings announcement on Monday, November 16th 2020.
View our earnings forecast for T2 Biosystems

How were T2 Biosystems' earnings last quarter?

T2 Biosystems Inc (NASDAQ:TTOO) posted its quarterly earnings results on Tuesday, August, 11th. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.15) by $0.06. The medical equipment provider earned $2.55 million during the quarter, compared to the consensus estimate of $2.50 million.
View T2 Biosystems' earnings history

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, August, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $18-20 million, compared to the consensus revenue estimate of $14.55 million.

What price target have analysts set for TTOO?

5 Wall Street analysts have issued 1-year price targets for T2 Biosystems' shares. Their forecasts range from $3.00 to $4.00. On average, they expect T2 Biosystems' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 184.6% from the stock's current price.
View analysts' price targets for T2 Biosystems

Who are some of T2 Biosystems' key competitors?

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), Heat Biologics (HTBX), Opko Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), NVIDIA (NVDA) and Vaxart (VXRT).

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the following people:
  • Prof. Michael J. Cima, Co-Founder & Independent Director (Age 60, Pay $62.5k)
  • Mr. Alec Barclay, Sr. VP of Operations (Age 39, Pay $477.4k)
  • Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 41, Pay $473.93k)
  • Mr. John J. Sperzel III, Pres, CEO & Director (Age 56)
  • Dr. Tyler E. Jacks, Co-Founder (Age 59)

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by many different institutional and retail investors. Top institutional investors include Bridgeway Capital Management Inc. (0.27%), Advisor Group Holdings Inc. (0.08%), Levin Capital Strategies L.P. (0.06%), Ironwood Financial llc (0.05%), Engineers Gate Manager LP (0.04%) and HighTower Advisors LLC (0.04%). Company insiders that own T2 Biosystems stock include Alec Barclay, David B Elsbree, John Mcdonough, Michael J Cima, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery.
View institutional ownership trends for T2 Biosystems

Which institutional investors are selling T2 Biosystems stock?

TTOO stock was sold by a variety of institutional investors in the last quarter, including Ironwood Financial llc, and Levin Capital Strategies L.P.. Company insiders that have sold T2 Biosystems company stock in the last year include Alec Barclay, David B Elsbree, John Mcdonough, and Thomas J Lowery.
View insider buying and selling activity for T2 Biosystems

Which institutional investors are buying T2 Biosystems stock?

TTOO stock was purchased by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Advisor Group Holdings Inc., Engineers Gate Manager LP, Charles Schwab Investment Management Inc., Jane Street Group LLC, Bank of New York Mellon Corp, McAdam LLC, and HighTower Advisors LLC.
View insider buying and selling activity for T2 Biosystems

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $1.23.

How big of a company is T2 Biosystems?

T2 Biosystems has a market capitalization of $181.98 million and generates $8.34 million in revenue each year. The medical equipment provider earns $-59,010,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. T2 Biosystems employs 151 workers across the globe.

What is T2 Biosystems' official website?

The official website for T2 Biosystems is www.t2biosystems.com.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.